Kit and detection method related to ovarian cancer and precancerous lesions thereof
Through miRNA combination kit and detection method, the total RNA extraction and logistic regression model are used to solve the problems of low sensitivity and insufficient specificity in ovarian cancer detection, achieving high accuracy and non-invasive early detection, reducing detection costs and traumatic.
Patent Information
- Application Number
- CN202411150615.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-12
AI Technical Summary
The existing ovarian cancer detection technology has problems such as low sensitivity, insufficient specificity, high detection cost, complex operation and strong invasiveness, making it difficult to achieve early diagnosis and accurate diagnosis.
Using miRNA combination kit and detection method, ovarian cancer and precancerous lesions were performed through total RNA extraction, reverse transcription reaction, PCR amplification and fluorescence detection, specific stem ring primers and fluorescence quantitative probe method combined with logistic regression model. early detection.
It improves the accuracy and sensitivity of ovarian cancer detection, reduces traumaticity to patients, simplifies the operation process, reduces false negative and false positive errors, and realizes non-invasive testing.
Smart Images

Figure CN118932061A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of detection technology, and in particular to a kit and a detection method related to ovarian cancer and precancerous lesions thereof. Background Art
[0002] Ovarian cancer (OC) is a common malignant tumor of the female reproductive system, ranking third in the incidence of female malignant tumors in the world, and its mortality rate ranks first among gynecological malignancies. Epidemiological surveys show that the standardized incidence and mortality of ovarian cancer in Chinese women increased significantly from 1990 to 2019, and the disease burden related to ovarian cancer also increased significantly. Ovarian cancer has an insidious onset and is difficult to diagnose. There is currently a lack of effective early screening methods, and there is currently no effective clinical treatment for advanced patients, with a 5-year survival rate of less than 45%;
[0003] Common screening methods for ovarian cancer include ultrasound, CT examination and tumor marker examination. Common tumor markers on the market include serum carbohydrate antigen 125 (CA125), human epididymis protein (HE4), alpha-fetoprotein, etc. However, the above screening methods lack sensitivity and specificity and cannot effectively detect the early stages of ovarian cancer. Therefore, it is urgent to find a non-invasive marker with high sensitivity and good specificity to assist in the early diagnosis and treatment of ovarian cancer.
[0004] MicroRNA (miRNA) is a type of small non-coding single-stranded RNA with a length of about 22 nucleotides. It plays an important role in regulating gene expression by inhibiting mRNA translation or promoting its degradation. miRNA has the advantages of high stability and strong specificity. It is not only expressed in tissues, but also stably exists in peripheral blood. Studies have shown that abnormal expression of miRNA is closely related to the formation and progression of tumors. In recent years, miRNA has attracted much attention as a new tumor marker. In the early stages of lung cancer, colon cancer and other cancers, up-regulated or down-regulated abnormal expression of miRNA has been found. Currently, there are many authorized patents for using miRNA to achieve early detection or prognosis monitoring of cancers such as gastric cancer, colon cancer and breast cancer.
[0005] For example, patent number CN104630377 is a breast cancer miRNA detection kit and its miRNA application, patent number CN106282360 is a plasma miRNA combination for predicting metastasis of colon cancer, its probe composition and application, patent number CN111575374 is used for early pancreatic pancreatic tumor detection molecular markers, its detection method and application. Based on the advantages of miRNA being non-invasive, highly stable and highly specific, finding and discovering miRNA related to ovarian cancer and applying it to early detection, diagnosis, accompanying and prognosis monitoring of ovarian cancer will have great significance and clinical value;
[0006] The existing methods have more or less defects in promotion, such as high reagent detection cost, complex operation, easy contamination, and certain false negatives and false positives.
[0007] Color Doppler ultrasound examination: After the patient's bladder is full, the patient's abdominal effusion, the relationship between the mass and surrounding organs, the boundary, size and shape and other parameters can be observed, as well as the richness of tumor blood vessels and blood flow distribution. The examination is non-radioactive, non-invasive, low-cost and simple to perform. It can monitor the patient's tumor lesions in real time and dynamically. The patient can be examined repeatedly in a short period of time without affecting the progression of the patient's disease. However, in the early diagnosis of ovarian cancer, the accuracy of ultrasound diagnosis is low;
[0008] Multislice spiral CT (MSCT) examination: Currently, it is the main imaging method for clinical diagnosis of ovarian cancer. It can clearly show the relationship between the tumor anatomical structure and surrounding tissues, and can achieve quantitative analysis based on the tumor blood flow, which is helpful for disease diagnosis. However, it is also easily affected by factors such as operator level and inflammation, leading to misdiagnosis.
[0009] Tumor marker detection: The tumor markers commonly used in clinical practice include carbohydrate antigen 125 (CA125) and human epididymis secretory protein (HE4). However, CA125 is not only expressed at elevated levels in ovarian malignant tumors, but also in patients with benign ovarian tumors, endometriosis, and pelvic inflammatory diseases. CA125 has a low specificity in the diagnosis of ovarian cancer. HE4 is the most commonly upregulated gene in ovarian cancer, but studies have found that some patients who have been diagnosed with ovarian cancer may have normal levels of HE4, and HE4 is rarely expressed in mucin-type ovarian cancer or germ cell ovarian cancer. At this stage, more combined tests are used to improve the diagnostic efficiency of ovarian cancer.
[0010] Pathological histological examination: Pathological histological examination is required for diagnosis. Tumor puncture biopsy or laparoscopic exploration to obtain biopsy tissue for pathological examination is recommended first. This type of examination can clarify the pathology of the patient's ovarian cyst, but it depends on the operator's operation skills. Improper operation or operational errors can easily result in unqualified puncture tissue, causing certain errors in the diagnosis results, and repeated punctures will cause great pain to patients. At the same time, due to the invasiveness of pathological histological examinations, patients often have low compliance. Summary of the invention
[0011] The present application aims to solve the technical problems of traditional detection technology, such as high technical requirements for personnel, low detection sensitivity, and inability to achieve early detection, and to provide a kit and detection method related to ovarian cancer and its precancerous lesions.
[0012] This application adopts the following technical means to solve the technical problem: a kit and detection method related to ovarian cancer and its precancerous lesions,
[0013] A kit and a detection method related to ovarian cancer and precancerous lesions thereof, the method comprising:
[0014] Total RNA extraction: obtain the user's serum sample, lyse the serum sample with RNAiso Blood, add chloroform and fully centrifuge. After centrifugation, the RNA is located in the supernatant layer. After aspirating the supernatant layer, the Total RNA can be recovered by isopropanol precipitation;
[0015] Reverse transcription reaction, using the stem-loop primer method to design specific reverse transcription primers to extend miRNA;
[0016] PCR amplification and fluorescence detection, using the probe method for fluorescence quantification of miRNA.
[0017] Further, in the step of obtaining a serum sample from a user, lysing the serum sample by RNAiso Blood, adding chloroform and fully centrifuging, the RNA is located in the supernatant after centrifugation, and the supernatant is aspirated and precipitated by isopropanol to recover TotalRNA,
[0018] Lysis: Take 250 μL of the sample to be tested, the positive control, and the negative control, and add them to 1.5 mL centrifuge tubes, add 750 μL RNAiso Blood, vortex or pipette up and down to mix to form a homogenized lysis solution, and let it stand at room temperature for 5 minutes;
[0019] Layering: Add 200 μL of chloroform to the homogenized lysate, cover the centrifuge tube tightly, mix until the solution is emulsified and milky white, and let stand at room temperature for 5 minutes;
[0020] After standing, centrifuge at 12,000 × g and 4°C for 15 min;
[0021] Pipette the supernatant and transfer it to a new centrifuge tube;
[0022] Precipitation: Add an equal volume of isopropanol to the supernatant, mix thoroughly by inverting the tube, and let stand at room temperature for 10 minutes;
[0023] After standing, centrifuge at 12,000 × g and 4°C for 10 min;
[0024] Washing: discard the supernatant, add 1 mL of 75% ethanol, mix well, centrifuge at 7,500 × g, 4°C for 5 min, and discard the supernatant;
[0025] Dissolution: Open the tube cap and let it dry naturally at room temperature. After drying, add 20 μL of RNase-free H2O to dissolve the RNA.
[0026] Furthermore, in the step of extending the miRNA by designing a specific reverse transcription primer by the stem-loop primer method,
[0027] Removal of genomic DNA: Prepare the reaction solution on ice. Prepare the reaction solution according to the table;
[0028] Prepare the reaction mixture on ice and add it to the reaction tube after the genomic DNA removal reaction is completed;
[0029] Carry out the following procedure in a thermal cycler: 42°C 15 min → 85°C 5 sec → 4°C; after the reaction, store the reverse transcribed cDNA in a -20°C freezer or immediately perform polymerase chain reaction.
[0030] Furthermore, in the step of using the probe method to perform fluorescence quantification of miRNA,
[0031] Before use, gently mix the reagent by turning it upside down, prepare the reaction solution on ice, and perform the PCR reaction on a fluorescent quantitative PCR instrument, selecting the Fam fluorescent channel.
[0032] Furthermore, the kit comprises:
[0033] miRNA combination, the miRNA combination comprising mir-200a, mir-200b, mir-200c, mir-201, mir-6782, mir-373, mir-130a, mir-1228-5p, mir-8073, mir-6756-5p, mir-3663-3p, mir-4697-5p, mir-6784-5p, mir-1307-3p, mir-1228-3p, mir-328-5p, mir-6821-5p, mir-1268, wherein mir-200a is hsa-mir-200a-p, mir-200b is hsa-mir-200b-p, mir-200c is hsa-mir-200c-p, mir-6782 is hsa-mir-6782, mir-373 is hsa-mir -373, mir-130 is hsa-mir-130, mir-1228-5p is hsa-mir-1228-5p, mir-8073 is hsa-mir-8073, mir-6756-5p is hsa-mir-6756-5p, mir-3663-3p is hsa-mir-3663-3p, mir-4697-5p is hsa-mir-4697-5p, mir-6784-5p is hsa-mir-6784-5p, mir-1307-3p is hsa-mir-1307-3p, mir-1228-3p is hsa-mir-1228-3p, mir-328-5p is hsa-mir-328-5p, mir-6821-5p is hsa-mir-6821-5p, and mir-1268 is hsa-mir-1268.
[0034] Furthermore, the optimal internal reference is hsa-mir-16-5p.
[0035] A kit and a detection method related to ovarian cancer and precancerous lesions thereof, the kit comprising:
[0036] Using logistic regression model
[0037] The formula for the logistic regression model is as follows
[0038] Y=-0.534*Amir-200a-1.322*Bmir-200b-0.622*Cmir-200c-0.257*Dmir-221-1.729*Emir-6782-5.356;
[0039] Among them, Amir-200a is the expression level of mir-200a (2-△△CT value), Bmir-200b is the expression level of mir-200b (2-△△CT value), Cmir-200c is the expression level of mir-200c (2-△△CT value), Dmir-221 is the expression level of mir-221 (2-△△CT value), and Emir-6782 is the expression level of mir-6782 (2-△△CT value).
[0040] Furthermore, when judging, when the calculated value is ≥ the threshold value of 0.64, it is determined to be a high-risk group for ovarian cancer; when the calculated value is <0.64, it is determined to be a low-risk group for ovarian cancer.
[0041] The present application provides a kit and a detection method related to ovarian cancer and its precancerous lesions, which have the following beneficial effects:
[0042] (1) High accuracy: Existing methods for diagnosing ovarian cancer mainly rely on ultrasound and CT, with the aid of tumor markers such as CA125 and HE4 to make disease judgments. However, imaging detection is not sensitive enough and requires high technical staff. Often, when imaging detection is performed, the patient has missed the best time for surgical treatment and is difficult to cure. MiRNA has great advantages in cancer detection, but the accuracy of using a single miRNA may be limited. This technology detects miRNA content through multiple PCR technology and improves detection accuracy through joint analysis.
[0043] (2) High sensitivity: This technology designs specific stem-loop primers for miRNA and optimizes the optimal concentration. It also uses the fluorescent quantitative probe method to design specific probes to effectively improve the sensitivity of the reaction.
[0044] (3) Good compliance: The corresponding miRNA can be detected by extracting RNA from the patient's blood, which effectively avoids invasive testing for patients and reduces the radiation damage of imaging examinations to the human body, making it more acceptable to patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 This is a combined diagnosis ROC curve diagram of an embodiment of a kit and a detection method related to ovarian cancer and precancerous lesions of the present application;
[0046] Figure 2 (a) Mir-200a ROC curve diagram of one embodiment of the kit and detection method for ovarian cancer and precancerous lesions of the present application;
[0047] Figure 3 (b) Mir-200b ROC curve diagram of one embodiment of the kit and detection method for ovarian cancer and precancerous lesions of the present application;
[0048] Figure 4 This is a Mir-200c ROC curve diagram of one embodiment of a kit and a detection method related to ovarian cancer and precancerous lesions of the present application;
[0049] Figure 5 This is a Mir-221 ROC curve diagram of an embodiment of a kit and a detection method related to ovarian cancer and precancerous lesions of the present application;
[0050] Figure 6 This is a Mir-221 ROC curve diagram of one embodiment of the kit and detection method related to ovarian cancer and precancerous lesions of the present application.
[0051] The implementation, functional features and advantages of the present application will be further described in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION
[0052] It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.
[0053] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.
[0054] It should be noted that the terms "include", "comprises" and "have" and any variations thereof in the specification and claims of the present application and the above-mentioned drawings are intended to cover non-exclusive inclusions. For example, a process, method, system, product or device that includes a series of steps or units is not limited to the listed steps or units, but may optionally include steps or units that are not listed, or may optionally include other steps or units that are inherent to these processes, methods, products or devices. In the claims, specification and drawings of the present application, relational terms such as "first" and "second" are merely used to distinguish one entity / operation / object from another entity / operation / object, and do not necessarily require or imply any such actual relationship or order between these entities / operations / objects.
[0055] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.
[0056] Reference Figure 1-6 , is a ROC curve diagram of the combined diagnosis of the kit and detection method related to ovarian cancer and its precancerous lesions in one embodiment of the present application;
[0057] Embodiment 1
[0058] A kit and a detection method related to ovarian cancer and precancerous lesions thereof, the method comprising:
[0059] Total RNA extraction: obtain the user's serum sample, lyse the serum sample with RNAiso Blood, add chloroform and fully centrifuge. After centrifugation, the RNA is located in the supernatant layer. After aspirating the supernatant layer, the Total RNA can be recovered by isopropanol precipitation;
[0060] Reverse transcription reaction, using the stem-loop primer method to design specific reverse transcription primers to extend miRNA;
[0061] Specifically, a stem-loop primer is a long primer that can self-cyclize, and its length is about 45bp. The stem-loop primer consists of three parts. One part is a universal sequence that can bind to the PCR downstream primer during the PCR reaction; the second part is the primer Tm value adjustment region; the third part is a specific sequence for a certain miRNA, and the sequence of this part is the reverse complementary sequence of 6-8 bases at the 3' end of a specific miRNA.
[0062] PCR amplification and fluorescence detection, using the probe method for fluorescence quantification of miRNA.
[0063] Specifically, specific stem-loop primers and TaqMan probes are designed for miRNA and internal reference. The probes specifically bind to the DNA template in the primer amplification region. In the PCR extension reaction, the Taq enzyme uses the exonuclease activity to cut the 5'-end fluorescent group of the probe. The probe is free in the reaction system, receives light stimulation and emits fluorescence for instrument detection, thereby realizing the detection of miRNA.
[0064] In the step of obtaining a serum sample from a user, lysing the serum sample by RNAiso Blood, adding chloroform and fully centrifuging, the RNA is located in the supernatant after centrifugation, and the supernatant is aspirated and precipitated by isopropanol to recover the Total RNA,
[0065] Lysis: Take 250 μL of the sample to be tested, the positive control, and the negative control, and add them to 1.5 mL centrifuge tubes, add 750 μL RNAiso Blood, vortex or pipette up and down to mix to form a homogenized lysis solution, and let it stand at room temperature for 5 minutes;
[0066] Layering: Add 200 μL of chloroform to the homogenized lysate, cover the centrifuge tube tightly, mix until the solution is emulsified and milky white, and let stand at room temperature for 5 minutes;
[0067] After standing, centrifuge at 12,000 × g and 4°C for 15 min;
[0068] Pipette the supernatant and transfer it to a new centrifuge tube;
[0069] Precipitation: Add an equal volume of isopropanol to the supernatant, mix thoroughly by inverting the tube, and let stand at room temperature for 10 minutes;
[0070] After standing, centrifuge at 12,000 × g and 4°C for 10 min;
[0071] Washing: discard the supernatant, add 1 mL of 75% ethanol, mix well, centrifuge at 7,500 × g, 4°C for 5 min, and discard the supernatant;
[0072] Dissolution: Open the tube cap and let it dry naturally at room temperature. After drying, add 20 μL of RNase-free H2O to dissolve the RNA.
[0073] In this embodiment, in the step of designing a specific reverse transcription primer by the stem-loop primer method to extend the miRNA,
[0074] Removal of genomic DNA: Prepare the reaction solution on ice. Prepare the reaction solution according to the table;
[0075] Specifically, the genome removal reaction reagent configuration table is as follows:
[0076] Reaction reagent amount / well
[0077] 5×gDNA Eraser Buffer / 2μL
[0078] gDNA Eraser / 1μL
[0079] Total RNA / 50ng
[0080] RNase Free ddH2Oto / 10μL
[0081] Reverse transcription reaction: Prepare the reaction mixture on ice according to the following ingredients and add it to the reaction tube after the genomic DNA removal reaction is completed;
[0082] The reverse transcription reaction reagent configuration table is as follows:
[0083] Reaction reagent amount / well
[0084] Reaction solution from step a / 10 μL
[0085] RT Enzyme Mix / 1μL
[0086] 5×RT Buffer / 4μL
[0087] RT Primer Mix / 2μL
[0088] RNase Free ddH2O to 20μL
[0089] Prepare the reaction mixture on ice and add it to the reaction tube after the genomic DNA removal reaction is completed;
[0090] Carry out the following procedure in a thermal cycler: 42°C 15 min → 85°C 5 sec → 4°C; after the reaction, store the reverse transcribed cDNA in a -20°C freezer or immediately perform polymerase chain reaction.
[0091] In this embodiment, in the step of using the probe method to perform fluorescence quantification of miRNA,
[0092] Before use, gently mix the reagent by turning it upside down, prepare the reaction solution on ice, and perform the PCR reaction on a fluorescent quantitative PCR instrument, selecting the Fam fluorescent channel.
[0093] The reaction configuration and reaction program settings are as follows:
[0094] Fluorescence quantitative PCR reaction reagent configuration table
[0095] Reagent / Usage Volume (μL)
[0096] Probe qPCR Mix (2×) / 5.0μL
[0097] qPCR Primer & Probe Mix / 1.5μL
[0098] cDNA / 1.0μL
[0099] RNase-free ddH2O / 2.5μL
[0100] Total / 10.0μL
[0101] Fluorescence quantitative PCR reaction program setting table
[0102] Reaction stage / temperature / time / number of cycles
[0103] Pre-denaturation / 95℃ / 30sec / 1
[0104] PCR reaction / 95℃ / 5sec / 45
[0105] PCR reaction / 60℃ / 30sec45
[0106] A kit and a detection method related to ovarian cancer and precancerous lesions thereof, the kit comprising:
[0107] miRNA combination, the miRNA combination comprising mir-200a, mir-200b, mir-200c, mir-201, mir-6782, mir-373, mir-130a, mir-1228-5p, mir-8073, mir-6756-5p, mir-3663-3p, mir-4697-5p, mir-6784-5p, mir-1307-3p, mir-1228-3p, mir-328-5p, mir-6821-5p, mir-1268, wherein mir-200a is hsa-mir-200a-p, mir-200b is hsa-mir-200b-p, mir-200c is hsa-mir-200c-p, mir-6782 is hsa-mir-6782, mir-373 is hsa-mir -373, mir-130 is hsa-mir-130, mir-1228-5p is hsa-mir-1228-5p, mir-8073 is hsa-mir-8073, mir-6756-5p is hsa-mir-6756-5p, mir-3663-3p is hsa-mir-3663-3p, mir-4697-5p is hsa-mir-4697-5p, mir-6784-5p is hsa-mir-6784-5p, mir-1307-3p is hsa-mir-1307-3p, mir-1228-3p is hsa-mir-1228-3p, mir-328-5p is hsa-mir-328-5p, mir-6821-5p is hsa-mir-6821-5p, and mir-1268 is hsa-mir-1268.
[0108] Specifically,
[0109] In this embodiment, the best preferred internal reference is hsa-mir-16-5p.
[0110] The kit uses the quantitative results obtained by the core diagnostic combination test to analyze the distribution of miRNA in the sample serum and determine the patient's pathological status.
[0111] In this embodiment,
[0112] Using logistic regression model
[0113] The formula for the logistic regression model is as follows
[0114] Y=-0.534*A mir-200a -1.322*B mir-200b -0.622*C mir-200c -0.257*D mir-221 -1.729*E mir-6782 -5.356;
[0116] Among them, A mir-200a is the expression level of mi r-200a (2 -△△CT value), B mir-200b is the expression level of mi r-200b (2 -△△CT value), C mir-200c is the expression level of mi r-200c (2 -△△CT value), D mir-221 is the expression level of mi r-221 (2 -△△CT value), E mir-6782 is the expression level of mi r-6782 (2 -△△CT value).
[0117] When making a judgment, when the calculated value is ≥ the threshold value of 0.64, the patient is judged to be at high risk of ovarian cancer; when the calculated value is <0.64, the patient is judged to be at low risk of ovarian cancer.
[0118] The kit contains reverse transcription primers, fluorescent quantitative upstream primers, downstream primers and fluorescent quantitative probes for detecting Mir-200a, Mir-200b, Mir-200c, Mir-221, Mir-6782 and Mir-16; wherein the reverse transcription primer sequences for detecting Mir-200a, Mir-200b, Mir-200c, Mir-221, Mir-6782 and Mir-16 are composed of single-stranded DNA, the fluorescent quantitative upstream and downstream primers are each composed of two single-stranded DNAs, and the fluorescent quantitative probe is composed of single-stranded DNA; the reverse transcription primer sequences are as shown in the table below, the fluorescent quantitative upstream and downstream primer sequences, and the fluorescent quantitative probe sequences are as shown in the table below;
[0119] In the kit, the RT Primer Mix in the reverse transcription step contains reverse transcription primers for detecting Mir-200a, Mir-200b, Mir-200c, Mir-221, Mir-6782, and Mir-16;
[0120] In the kit, the recommended final concentration of the reverse transcription primers Mir-200a, Mir-200b, Mir-200c, Mir-221, Mir-6782, and Mir-16 in the RT Primer Mix in the reverse transcription step is 5uM;
[0121] In the kit, the qPCR Primer & Probe Mix in the fluorescent quantitative PCR reaction reagent contains fluorescent quantitative upstream primers, downstream primers and fluorescent probes for detecting Mir-200a, Mir-200b, Mir-200c, Mir-221, Mir-6782 and Mir-16;
[0122] In the kit, the 5' end of the nucleotide sequence of the fluorescent probe in the fluorescent quantitative PCR is labeled with a FAM fluorescent reporter group, and the 3' end is labeled with a BHQ fluorescent quencher group;
[0123] In the kit, the qPCR Primer & Probe Mix in the fluorescent quantitative PCR reaction reagent contains fluorescent quantitative upstream primers and downstream primers for detecting Mir-200a, Mir-200b, Mir-200c, Mir-221, Mir-6782, and Mir-16, and the final concentration is recommended to be 10 μM, and the fluorescent probe concentration is recommended to be 10 μM;
[0124] Table qPCR Primer & Probe Mix configuration scheme
[0125] Raw material name / dosage
[0126] miR-Probe (10 μM) / 0.3 μL
[0127] miR-Forward (10 μM) / 0.6 μL
[0128] miR-Reverse (10μM) / 0.6μL
[0129] The kit also contains reagents such as genome removal reagent, reverse transcriptase, PCR enzyme, buffer, RNase-free ddH2O, etc.;
[0130] The kit is suitable for fluorescence quantitative PCR instruments such as ABI-7500 and Roche Light Cycler480.
[0131] The core miRNA diagnostic combination primers and probe sequences designed in the kit are as follows:
[0132]
[0133]
[0134]
[0135] In summary, the kit detects the stability of serum expression
[0136] Serum from 10 ovarian cancer patients and 10 healthy subjects were selected for stability evaluation. The test kit detection method was used to collect serum from the experimental subjects for three consecutive times (once every other week). The results showed that there was no significant difference in the internal reference Mir-16 between ovarian cancer serum and healthy serum, and the standard deviation was <1.0; the expression levels of Mir-200a, Mir-200b, Mir-200c, Mir-221, and Mir-6782 in the serum of ovarian cancer patients were higher than those in the serum of healthy subjects, and the analysis showed significant differences, suggesting that it can be used as a marker for ovarian cancer detection.
[0137] Detection of clinical samples by the kit
[0138] The kit was used to extract Total RNA, reverse transcription reaction, PCR amplification and fluorescence detection of 50 collected ovarian cancer positive samples and 50 healthy negative samples according to the step requirements, and the expression level of miRNA in the samples was detected. The detection results were analyzed by logistic regression using software. The results showed that the AUC of Mir-200a, Mir-200b, Mir-200c, Mir-221 and Mir-6782 under the combined detection was 97.9% (area under the ROC curve), and the AUC of Mir-200a, Mir-200b, Mir-200c, Mir-221 and Mir-6782 when detected alone was 81.6%, 84.9%, 74.7%, 74.2% and 93.4% respectively. By comparison, it can be seen that the AUC under the combined detection is greater than the AUC when detected alone, which has better diagnostic significance. At this time, the sensitivity of the combined detection is 94.7% and the specificity is 95%, which has an advantage in the detection of ovarian cancer.
[0139] Those skilled in the art will appreciate that embodiments of the present invention may be provided as methods, systems, or computer program products. Therefore, the present invention may take the form of a complete hardware embodiment, a complete software embodiment, or an embodiment combining software and hardware. Moreover, the present invention may take the form of a computer program product implemented on one or more computer-usable storage media (including but not limited to disk storage, CD-ROM, optical storage, etc.) containing computer-usable program code.
[0140] The present invention is described with reference to flowcharts and / or block diagrams of methods, devices (systems) and computer program products according to embodiments of the present invention. It should be understood that each process and / or block in the flowchart and / or block diagram, as well as the combination of processes and / or blocks in the flowchart and / or block diagram, can be implemented by computer program instructions. These computer program instructions can be provided to a processor of a general-purpose computer, a special-purpose computer, an embedded processor or other programmable data processing device to produce a machine, so that the instructions executed by the processor of the computer or other programmable data processing device generate instructions for implementing the process in the flowchart. Figure 1 A process or multiple processes and / or boxes Figure 1 A device that provides the functions specified in a block or multiple blocks.
[0141] These computer program instructions may also be stored in a computer-readable memory capable of directing a computer or other programmable data processing device to operate in a specific manner, so that the instructions stored in the computer-readable memory produce an article of manufacture comprising an instruction device, which implements the process Figure 1 A process or multiple processes and / or boxes Figure 1 A function specified in one or more boxes.
[0142] These computer program instructions can also be loaded onto a computer or other programmable data processing device so that a series of operating steps are executed on the computer or other programmable device to produce a computer-implemented process, thereby providing instructions for implementing the process. Figure 1 A process or multiple processes and / or boxes Figure 1 A step that specifies a function in one or more boxes.
[0143] Although the embodiments of the present application have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present application, and that the scope of the present application is defined by the appended claims and their equivalents.
Claims
1. A kit and a detection method for ovarian cancer and its precancerous lesions, It is characterized in that The method comprises: Total RNA extraction: obtain the user's serum sample, lyse the serum sample with RNAiso Blood, add chloroform and fully centrifuge. After centrifugation, the RNA is located in the supernatant layer. After aspirating the supernatant layer, the total RNA can be recovered by isopropanol precipitation; Reverse transcription reaction, using the stem-loop primer method to design specific reverse transcription primers to extend miRNA; PCR amplification and fluorescence detection, using the probe method for fluorescence quantification of miRNA.
2. The kit and detection method for ovarian cancer and its precancerous lesions according to claim 1, It is characterized in that In the step of obtaining a serum sample from a user, lysing the serum sample by RNAiso Blood, adding chloroform and fully centrifuging, the RNA is located in the supernatant after centrifugation, and the supernatant is aspirated and precipitated by isopropanol to recover the Total RNA, Lysis: Take 250 μL of the sample to be tested, the positive control, and the negative control, and add them to 1.5 mL centrifuge tubes, add 750 μL RNAiso Blood, vortex or pipette up and down to mix to form a homogenized lysis solution, and let it stand at room temperature for 5 minutes; Layering: Add 200 μL of chloroform to the homogenized lysate, cover the centrifuge tube tightly, mix until the solution is emulsified and milky white, and let stand at room temperature for 5 minutes; After standing, centrifuge at 12,000 × g and 4°C for 15 min; Pipette the supernatant and transfer it to a new centrifuge tube; Precipitation: Add an equal volume of isopropanol to the supernatant, mix thoroughly by inverting the tube, and let stand at room temperature for 10 minutes; After standing, centrifuge at 12,000 × g and 4°C for 10 min; Washing: discard the supernatant, add 1 mL of 75% ethanol, mix well, centrifuge at 7,500 × g, 4°C for 5 min, and discard the supernatant; Dissolution: Open the tube cap and let it dry naturally at room temperature. After drying, add 20 μL of RNase-free H2O to dissolve the RNA.
3. The kit and detection method for ovarian cancer and its precancerous lesions according to claim 1, It is characterized in that In the step of extending miRNA by designing a specific reverse transcription primer by the stem-loop primer method, Removal of genomic DNA: Prepare the reaction solution on ice. Prepare the reaction solution according to the table; Prepare the reaction mixture on ice and add it to the reaction tube after the genomic DNA removal reaction is completed; Carry out the following procedure in a thermal cycler: 42°C 15 min → 85°C 5 sec → 4°C; after the reaction, store the reverse transcribed cDNA in a -20°C freezer or immediately perform polymerase chain reaction.
4. The kit and detection method for ovarian cancer and its precancerous lesions according to claim 1, It is characterized in that In the step of using the probe method to perform fluorescence quantification of miRNA, Before use, gently mix the reagents by turning them upside down, prepare the reaction solution on ice, and perform the PCR reaction on a fluorescent quantitative PCR instrument, selecting the Fam fluorescent channel.
5. A kit and detection method for ovarian cancer and its precancerous lesions, It is characterized in that The kit comprises: miRNA combination, the miRNA combination comprising mir-200a, mir-200b, mir-200c, mir-201, mir-6782, mir-373, mir-130a, mir-1228-5p, mir-8073, mir-6756-5p, mir-3663-3p, mir-4697-5p, mir-6784-5p, mir-1307-3p, mir-1228-3p, mir-328-5p, mir-6821-5p, mir-1268, wherein mir-200a is hsa-mir-200a-p, mir-200b is hsa-mir-200b-p, mir-200c is hsa-mir-200c-p, mir-6782 is hsa-mir-6782, mir-373 is hsa-mir -373, mir-130 is hsa-mir-130, mir-1228-5p is hsa-mir-1228-5p, mir-8073 is hsa-mir-8073, mir-6756-5p is hsa-mir-6756-5p, mir-3663-3p is hsa-mir-3663-3p, mir-4697-5p is hsa-mir-4697-5p, mir-6784-5p is hsa-mir-6784-5p, mir-1307-3p is hsa-mir-1307-3p, mir-1228-3p is hsa-mir-1228-3p, mir-328-5p is hsa-mir-328-5p, mir-6821-5p is hsa-mir-6821-5p, and mir-1268 is hsa-mir-1268.
6. The kit and detection method for ovarian cancer and its precancerous lesions according to claim 5, It is characterized in that The best preferred internal reference is hsa-mir-16-5p.
7. The kit and detection method for ovarian cancer and its precancerous lesions according to claim 5, It is characterized in that Using logistic regression model The formula for the logistic regression model is as follows Y=-0.534*A mir-200a -1.322*B mir-200b -0.622*C mir-200c -0.257*D mir-221 -1.729*E mir-6782 -5.356; Among them, A mir-200a is the expression level of mir-200a (2 -△△CT value), B mir-200b is the expression level of mir-200b (2 -△△CT value), C mir-200c is the expression level of mir-200c (2 -△△CT value), D mir-221 is the expression level of mir-221 (2 -△△CT value), E mir-6782 is the expression level of mir-6782 (2 -△△CT value).
8. The kit and detection method for ovarian cancer and its precancerous lesions according to claim 5, It is characterized in that When judging, when the calculated value is ≥ the threshold value of 0.64, it is determined to be a high-risk group for ovarian cancer; When the calculated value is less than 0.64, the population is judged to be at low risk of ovarian cancer.
